I know some here would justifiably say that in the past, management has underperformed, (especially relative to their compensation) but Cryoport is not exactly resting on their laurels. Last quarter they brought in 2 executives for strategic sales and consulting, and converted a previously outsourced marketing and sales force in-house. They added 46 new biopharma accounts during the first six months of the year, and this was BEFORE they were FDA approved with Novartis. The logistics services are an integral part of the CMC section of the BLA filing, so passing that regulatory hurdle and validating their expertise and capabilities is YUGE! I think this will pay big dividends and help their sales and marketing efforts going forward. Cryoport has established a commanding leadership position and is attracting business from the largest and most successful pharmaceutical companies in the world. I fully expect this to continue, if not snowball.
I think 2017 is really the year of validation, not only for Cryoport, but also the “experimental” cell therapies. There were a lot of doubters with the approval process, safety, CMC manufacturing issues, etc. That has been answered, but now there are concerns about the costs of these new therapies, pushback from payers, and the abilities of all the companies to roll out these new therapies at scale. So 2018 will be the year of commercialization, and execution. Novartis seems well prepared, and because of the life-saving efficacy of Kymriah and agreement with payers, the uptake should be fairly quick. Actually, I think the same can be said for KITE; they are very well managed, and there is no standard of care for r/r DLBCL, so once approved, the ramping should also be quick. This means higher initial revenues for Cryoport than the analysts are projecting and I’m pretty sure they will be profitable next year.
I think you may be disappointed about dilution though, as I anticipate more. BTW, Is 9.5 million total warrants correct?
News 
Market Data 
Discover 
